The Latest

  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    10 clinical trials to watch in the second half of 2024

    Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Leqembi sales inch higher; Spark’s pivot leads to layoffs

    Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.

  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    Bristol Myers’ leukemia blockbuster set to face generic rivals

    Patent litigation has opened the door to generic copies of Bristol Myers’ Sprycel arriving in the U.S. as soon as September.

  • A person holds an insulin pen
    Image attribution tooltip
    agrobacter via Getty Images
    Image attribution tooltip

    Novo’s once-weekly insulin rejected by FDA

    The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing. 

  • A person in a blue suit speaks at a lectern.
    Image attribution tooltip
    Jerod Harris via Getty Images
    Image attribution tooltip

    Flagship raises $3.6B for biotech investing

    The latest round of funding comes as the biotech company creator adds executives and prepares to grow more life sciences startups.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Eli Lilly’s proposed $3.2 billion acquisition of Morphic Holdings extends the industry’s streak of dealmaking involving immune disease drugmakers.

    Updated July 8, 2024
  • Federal Trade Commission Chair Lina Khan testifies at a committee hearing.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    FTC to sue three largest PBMs over drug price practices: WSJ

    Antitrust regulators are set to file suit against CVS Caremark, Express Scripts and Optum Rx over how they negotiate discounts for drugs, including insulin, per the report.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip

    As GLP-1 drugs boom, other healthcare companies are cashing in

    With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and document new health benefits.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    AbbVie names new R&D head; Arcutis eczema cream approved

    Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.

  • A human brain is imaged with a MRI scan.
    Image attribution tooltip
    Popartic via Getty Images
    Image attribution tooltip

    UniQure stock surges on data for Huntington’s gene therapy

    The biotech’s stock rose more than 60% as fresh data appeared to alleviate some investor concerns about the therapy’s effectiveness and reliability.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Twelve biotechs went public between January and June, surpassing 2023's total over the same period but falling short of the pace set in each of the previous five years.

    Updated July 11, 2024
  • ftc federal trade commission
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    FTC criticizes PBM power over prescription drug market

    On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the expense of patients and independent pharmacists. 

  • A woman's hands over her abdomen.
    Image attribution tooltip
    Doucefleur via Getty Images
    Image attribution tooltip
    Emerging biotech

    SciRhom pulls in $70M for a new type of immune disease drug

    The Series A round will help the startup bring its lead candidate, an antibody aimed at the protein iRhom2, into human testing by the end of 2024.

  • A sign shows the logo of Eli Lilly's Research Laboratories
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip

    Lilly to buy Morphic in $3B bet on inflammation drug

    The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.

  • People stand on a dock below a large cruise ship
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    HilleVax’s norovirus vaccine ineffective in large trial of infants

    Shares in HilleVax plummeted after the company reported its experimental shot failed to meet the primary and secondary goals of the Phase 2b study.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire here.

    In addition to Sprycel’s looming patent expiration, Bristol Myers faces the prospect of generic competitors to Eliquis and Opdivo arriving later this decade.

    Updated May 13, 2024
  • Myricx Bio co-founders Andrew Bell, Roberto Solari and Ed Tate, and CEO Robin Carr in a laboratory.
    Image attribution tooltip
    Permission granted by Myricx Bio
    Image attribution tooltip

    A London biotech raises $114M to hone a new ADC payload

    Myricx Bio is developing a type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Ligand to buy Apeiron; Roche reports another TIGIT setback

    Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.

  • Employees of CureVac work in a laboratory
    Image attribution tooltip
    Courtesy of CureVac
    Image attribution tooltip

    CureVac cuts jobs, licenses out vaccines to GSK

    The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna gets US funding for bird flu vaccine development

    BARDA will provide Moderna with $176 million to advance late-stage testing of an H5 influenza shot, as health officials monitor animal outbreaks.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit

    Forbion led the startup’s Series B round. Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD.

  • A U.S. flag flying above a building showing a sign with the word Lilly written in red.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    New Alzheimer's drugs

    Lilly drug for Alzheimer’s approved by FDA

    The drug, which Lilly will sell as Kinsunla, carries a warning for the risk of a certain kind of imaging abnormality that can be serious in rare cases.

    Updated July 2, 2024
    FDA
  • An illustration of immune system T cells attacking cancer cells.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Cartesian data add to progress, questions for CAR-T in autoimmune disease

    The company claimed Phase 2 study results prove the therapy’s promise treating myasthenia gravis. But shares lost more than a quarter of their value amid questions about the data.

  • A sign showing the Eisai logo outside of a building
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip

    Eisai and Bristol Myers cancel cancer ADC deal

    The Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Eli Lilly inks another radiopharma deal, gaining option to buy startup

    Under an arrangement with Radionetics, Lilly will have rights to acquire the San Diego biotechnology company for $1 billion.